---
title: "Available Products of Fecal Microbiota Transplantation"
date: "2023-02-02"
enableToc: false
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[fecal microbiota transplantation]]

# Available Products of Fecal Microbiota Transplantation

*   Potentially Practice-Changing

    Drug/Device Alert Updated 9 Dec 2022

    fecal microbiota, **live-jslm (Rebyota)** FDA approved for prevention of recurrence of *Clostridioides difficile* (CDI) in patients â‰¥ 18 years old who have completed antibiotic treatment for recurrent CDI
    *   not indicated for treatment of *C. difficile*
    *   fecal microbiota, live-jslm is from human fecal matter sourced from qualified donors
    *   efficacy based on 2 randomized trials including 301 adults receiving fecal microbiota, live-jslm vs. placebo
        *   CDI diarrhea defined as â‰¥ 3 unformed/loose stools in â‰¤ 24 hours for â‰¥ 2 consecutive days and a positive stool test for *C. difficile* toxin at time of diarrhea
        *   treatment success defined as the absence of CDI diarrhea within 8 weeks of blinded treatment
        *   overall estimated treatment success rate 70.6% vs. 57.5% (95% credible interval 2.3-24)
    *   dosing and administration
        *   thaw the product in a refrigerator for about 24 hours, do not thaw using heat source (such as hot water)
        *   administer fecal microbiota, live-jslm 24-72 hours after the last dose of antibiotics for CDI
        *   give 150 mL rectally once
        *   see [product information][36] for preparation and administration instruction
    *   adverse effects (in â‰¥ 3%) include abdominal distention/pain, diarrhea, flatulence, and nausea
    *   References - [FDA Press Release 2022 Nov 30][37], [FDA Label 2022 Nov][38]

---
title:Available Products of Fecal Microbiota Transplantation
date: "2023-02-02"
enableToc: false
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[fecal microbiota transplantation]]

# Available Products of Fecal Microbiota Transplantation

*   Potentially Practice-Changing

    Drug/Device Alert Updated 9 Dec 2022

    fecal microbiota, live-jslm (Rebyota) FDA approved for prevention of recurrence of *Clostridioides difficile* (CDI) in patients â‰¥ 18 years old who have completed antibiotic treatment for recurrent CDI
    *   not indicated for treatment of *C. difficile*
    *   fecal microbiota, live-jslm is from human fecal matter sourced from qualified donors
    *   efficacy based on 2 randomized trials including 301 adults receiving fecal microbiota, live-jslm vs. placebo
        *   CDI diarrhea defined as â‰¥ 3 unformed/loose stools in â‰¤ 24 hours for â‰¥ 2 consecutive days and a positive stool test for *C. difficile* toxin at time of diarrhea
        *   treatment success defined as the absence of CDI diarrhea within 8 weeks of blinded treatment
        *   overall estimated treatment success rate 70.6% vs. 57.5% (95% credible interval 2.3-24)
    *   dosing and administration
        *   thaw the product in a refrigerator for about 24 hours, do not thaw using heat source (such as hot water)
        *   administer fecal microbiota, live-jslm 24-72 hours after the last dose of antibiotics for CDI
        *   give 150 mL rectally once
        *   see [product information][36] for preparation and administration instruction
    *   adverse effects (in â‰¥ 3%) include abdominal distention/pain, diarrhea, flatulence, and nausea
    *   References - [FDA Press Release 2022 Nov 30][37], [FDA Label 2022 Nov][38]

